[Skip to Navigation]
[Skip to Navigation Landing]
Views 2,531
Citations 0
April 2017

Keratinocyte Cancer Therapies Enter the Era of Targeted and Immunotherapy: Join the Club

Author Affiliations
  • 1Department of Dermatology, Medical College of Wisconsin, Milwaukee
  • 2Divison of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee
JAMA Dermatol. 2017;153(4):253-255. doi:10.1001/jamadermatol.2017.0269

In the past 5 years, major advancements have been made in the systemic therapy of advanced and metastatic melanoma. As opposed to the robust research and clinical trials in melanoma, progress in the treatment of locally advanced and metastatic keratinocyte cancers (KC), such as cutaneous squamous cell carcinomas (cSCC) and basal cell carcinomas (BCC), has been lagging behind. The first targeted therapy was successfully introduced for advanced BCC using hedgehog pathway inhibitors and demonstrated good responses and a decent adverse effects profile. In this issue of JAMA Dermatology, 3 groups of authors discuss their findings about targeted therapy for sSCC1 and immunotherapy for cSCC2 and BCC.3